Abstract 40P
Background
This study aimed to examine MRI dynamic contrast-enhanced (DCE) imaging in various histological and molecular biological types of breast cancer.
Methods
To solve the set tasks, a clinical and instrumental examination was carried out of 70 women with a verified diagnosis of breast cancer who were examined and treated at the RSSPMCO&R in 2017–2019. The age of the patients was 26–75 years (mean age - 49.0 ± 2 years).
Results
For luminal A cancer (22 of 70 cases), the following MR signs were revealed: nodular formations more often had an irregular shape - 21 (95.5%), irregular (59.1%), less often spicular contours (27.3%). In 16 of 22 cases, a ring-shaped contrasting pattern was noted. Type III intensity-time curve at MRI with DCE was found in all 22 patients with luminal A subtype of breast cancer. It should be noted that all additional MR signs (retraction of the nipple, thickening and deformation of the skin over the formation) were found in luminal subtype A. The luminal B-subtype was detected in 20 patients (28.6%), with Her2/neu-positive luminal B-subtype noted in 12 patients, and Her2/neu-negative subtype in 8 cases. For these two subtypes of the masses visualized on MRI images were the same (irregular shape with indistinct contours, annular contrasting), but 4 of 12 patients with luminal Her2/neu-positive subtype had type II on MRI with DCE. The same type of curve was observed in 5 out of 11 patients (45.5%) with Her2/neu-positive breast cancer. At the same time, with luminal, subtype, luminal, Her2/neu-negative subtype, and three cases of negative breast cancer, type III of the dynamic contrast curve was always observed. Consequently, type II of the curve was observed only with negative Her2/neu types. In our studies, in 53% of triple-negative subtypes breast cancer was displayed on MR images with a rounded-oval or lobular shape, and in 17.6% with clear smooth (smooth) contours. But type III “intensity - time” curve, noted according to MRI data with DCE, testified to the malignant process in all 17 patients with triple-negative breast cancer.
Conclusions
Our studies have shown that the pathologically determined degree of differentiation of breast cancer and immunohistochemical types and subtypes affect the visualized morphological characteristics and its functional features, assessed by MRI with DCE.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Nishanova Yulduz.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
224P - Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with localized prostate cancer: A real-world, population-based study
Presenter: Atul Batra
Session: e-Poster Display Session
225P - Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort
Presenter: Michael Fernando
Session: e-Poster Display Session
226P - Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Andrew Jensen
Session: e-Poster Display Session
227P - Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
Presenter: Ulka Vaishampayan
Session: e-Poster Display Session
228P - Symptoms and impacts of metastatic castration-resistant prostate cancer (mCRPC) among Japanese patients designated to receive Ra-223
Presenter: Hiroji Uemura
Session: e-Poster Display Session
229P - Expanding the role of supervised exercise on fatigue in prostate cancer patient receiving androgen deprivation therapy: A meta-analysis of randomized controlled trial
Presenter: Niwanda Yogiswara
Session: e-Poster Display Session
230P - Molecular profiling and clinical characteristics of Chinese patients with prostate cancer
Presenter: Ranlu Liu
Session: e-Poster Display Session
231P - Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199
Presenter: Jeffrey Goh
Session: e-Poster Display Session
232P - Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience
Presenter: Rachel Raju
Session: e-Poster Display Session
243P - Target sequencing of 508 genes in Chinese epithelial ovarian cancer patients
Presenter: Li Lei
Session: e-Poster Display Session